[
    {
        "file_name": "INNOVIVA,INC_08_07_2014-EX-10.1-COLLABORATION AGREEMENT.txt",
        "perturbation": [
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "9.4 Supply of Collaboration Products for Commercialization. Subject to the terms and conditions of this Agreement, GSK shall obtain supply of the commercial requirements of formulated, packaged and labeled Collaboration Products. Such formulated, packaged and labeled Collaboration Products shall be manufactured and supplied in accordance with all applicable Laws and current Good Manufacturing Practices. GSK shall be solely responsible for secondary manufacture, packaging and labeling of the Collaboration Product.",
                "changed_text": "9.4 Supply of Collaboration Products for Commercialization. Subject to the terms and conditions of this Agreement, GSK shall obtain supply of the commercial requirements of formulated, packaged and labeled Collaboration Products. Such formulated, packaged and labeled Collaboration Products shall be manufactured and supplied in accordance with all applicable regulations and accepted industry practices. Theravance retains responsibility for secondary manufacture, packaging and labeling of the Collaboration Product.",
                "explanation": "The original text states GSK is solely responsible for secondary manufacture, packaging, and labeling. The modified text contradicts this by stating that Theravance retains responsibility for the same, creating confusion regarding responsibilities.",
                "location": "ARTICLE 9"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "11.3 Additional Theravance Representations and Warranties. Theravance further represents and warrants to GSK as of the Effective Date that:\n\n11.3.1 Having carried out and completed diligent searches in relation to the Theravance Patents, and other than as disclosed to GSK's counsel by Theravance's counsel, Theravance is not aware, nor has been made aware, of any conflict or likely future conflict with the intellectual property rights of any Third Party with respect to Theravance Patents.\n\nTheravance has not received notice from any Third Party of a claim that an issued patent of such Third Party would be infringed by the manufacture, distribution, marketing or sale of the Collaboration Products under this Agreement",
                "changed_text": "11.3 Additional Theravance Representations and Warranties. Theravance further represents and warrants to GSK as of the Effective Date that:\n\n11.3.1 Having carried out and completed diligent searches in relation to the Theravance Patents, and other than as disclosed to GSK's counsel by Theravance's counsel, Theravance makes no guarantees regarding conflicts or future conflicts with the intellectual property rights of any Third Party with respect to Theravance Patents.\n\nTheravance has received notice from a Third Party of a claim that an issued patent of such Third Party would be infringed by the manufacture, distribution, marketing or sale of the Collaboration Products under this Agreement",
                "explanation": "The original text presents a warranty that Theravance is not aware of any IP conflicts. The modified text replaces it with a statement offering no guarantee about IP conflicts and acknowledging an infringement claim, directly contradicting the original representation.",
                "location": "ARTICLE 11"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "4.2.1 General; GSK. Under the direction of the Joint Project Committee, specific Pooled Compounds will be identified from time to time and, as applicable, selected for Development as a Collaboration Product. The Joint Project Committee will determine the number and extent of Development of the Pooled Compounds and the criteria to be used for selecting among the eight Pooled Compounds and, subject to the other terms of this Agreement, will endeavor to move one or more such Collaboration Products forward in Development. In\nrelation to the foregoing, GSK shall have the overall responsibility for, and use Diligent Efforts in, the performance of all such Development activities which shall include, where applicable, relevant regulatory filings (as contemplated under Article 8) for any such Collaboration Product moved forward in Development. Further, GSK shall use Diligent Efforts to advance such Collaboration Product through Development in accordance with the Go/No-Go checkpoints identified in the then current Development Plan for such Collaboration Product. GSK shall also use Diligent Efforts to contribute at least one ICS and/or other non-LABA compound to the collaboration for the purpose of developing a combination product and Diligent Efforts to develop an optimal inhaled formulation of Collaboration Product in a device which may be either/or a dry powder inhaler formulation and/or a metered dose inhaler formulation of the Collaboration Compound and Development activities of such may continue in parallel.",
                "changed_text": "4.2.1 General; GSK. Under the direction of the Joint Project Committee, specific Pooled Compounds will be identified from time to time and, as applicable, selected for Development as a Collaboration Product. The Joint Project Committee will determine the number and extent of Development of the Pooled Compounds and the criteria to be used for selecting among the eight Pooled Compounds and, subject to the other terms of this Agreement, will endeavor to move one or more such Collaboration Products forward in Development. In\nrelation to the foregoing, Theravance shall have the overall responsibility for, and use Commercially Reasonable Efforts in, the performance of all such Development activities which shall include, where applicable, relevant regulatory filings (as contemplated under Article 8) for any such Collaboration Product moved forward in Development. Further, Theravance shall use Commercially Reasonable Efforts to advance such Collaboration Product through Development in accordance with the Go/No-Go checkpoints identified in the then current Development Plan for such Collaboration Product. Theravance may elect to contribute one ICS and/or other non-LABA compound to the collaboration for the purpose of developing a combination product and use Commercially Reasonable Efforts to develop an inhaled formulation of Collaboration Product in a device which may be either/or a dry powder inhaler formulation and/or a metered dose inhaler formulation of the Collaboration Compound and Development activities of such may continue in parallel.",
                "explanation": "The original text assigns GSK the overall responsibility for development activities and requires 'Diligent Efforts'. The modified text shifts this responsibility to Theravance and changes the standard to 'Commercially Reasonable Efforts'. This creates a conflict regarding who is responsible for development and the standard of effort required.",
                "location": "ARTICLE 4"
            }
        ]
    }
]